LIMK2

LIM kinase 2 (LIMK2) is a serine/threonine and tyrosine kinase that regulates actin cytoskeleton dynamics by controlling cofilin activity^[1][2]. Mechanistically, LIMK2 participates in the Rho family GTPase signaling pathways, influencing actin filament turnover, stress fiber formation, and cell migration^[1][2]. LIMK2 expression affects cell cycle progression, neuronal differentiation, and tumorigenesis, with dysregulation contributing to cancer metastasis, chemotherapy resistance, and neurofibromatosis-related pathologies^[3][1][4][5]. Compared with its isoform LIMK1, LIMK2 exhibits distinct subcellular localization, nuclear shuttling controlled by PKC-dependent phosphorylation at Ser-283, and specific roles in cofilin regulation that limit functional redundancy^[6]. LIMK2 also differs from LIMK2-1, a variant containing a protein phosphatase 1 (PP1) inhibitory domain, which modulates actin dynamics without directly phosphorylating cofilin^[7]. In experimental models, selective LIMK2 inhibitors such as T56-LIMKi reduce tumor growth, impair actin stress-fiber formation, and suppress cell migration, highlighting its utility as a pharmacological target^[4]. LIMK2 inhibition has demonstrated therapeutic potential in pancreatic cancer, glioma, and NF1-deficient cell models, emphasizing the importance of isoform-selective approaches for experimental and translational research^[4][8][9]. These findings collectively underscore LIMK2’s unique regulatory function within the LIM kinase family and its value for targeted studies in cytoskeletal and cancer biology.